Quoin Pharmaceuticals, Ltd. (QNRX)
Nasdaq: QNRX · Pharmaceutical Preparations · filing with the SEC since 2016
Who runs Quoin Pharmaceuticals, Ltd.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Myers Michael
Chief Executive Officer. First filing Jan 2023, latest Sep 1, 2026, 3 filings in all.
Officers reporting now
3
of 8 people with a filing in the last fifteen months
Directors reporting now
5
9 people on the record since 2023
Officerssales are open-market, Oct 26, 2025 to Oct 26, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Myers Michael | Chief Executive Officer | Jan 2023 | Sep 1, 2026 | none |
| Lawlor Sally Bridget | Chief Financial Officer | Sep 2025 | Sep 1, 2026 | none |
| Carter Denise P. | Chief Operating Officer | Jan 2023 | Sep 1, 2026 | none |
Directorssales are open-market, Oct 26, 2025 to Oct 26, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Langer Dennis | director | Jan 2023 | Oct 26, 2026 | none |
| Culverwell Anthony James | director | Jan 2023 | Sep 1, 2026 | none |
| Cooper Joseph Patrick | director | Jan 2023 | Feb 6, 2026 | none |
| Leong Natalie Ee Mun | director | Jan 2023 | Feb 6, 2026 | none |
| Sember Michael T | director | Mar 2023 | Feb 6, 2026 | none |
Owners of more than 10% of a classsales are open-market, Oct 26, 2025 to Oct 26, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 10% owner | Feb 2026 | Mar 31, 2026 | none |
Earlier names on the record1, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.